Wasserman Jason K, Nicholas Garth, Yaworski Rebecca, Wasserman Anne-Marie, Woulfe John M, Jansen Gerard H, Chakraborty Santanu, Nguyen Thanh B
Division of Laboratory Medicine, Department of Anatomical Pathology, Ottawa, Ontario, Canada; University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
PLoS One. 2015 Apr 7;10(4):e0123890. doi: 10.1371/journal.pone.0123890. eCollection 2015.
Glioblastoma can occur either de novo or by the transformation of a low grade tumour; the majority of which harbor a mutation in isocitrate dehydrogenase (IDH1). Anaplastic tumours are high-grade gliomas that may represent the final step in the evolution of a secondary glioblastoma or the initial presentation of an early primary glioblastoma. We sought to determine whether pathological and/or radiological variables exist that can reliably distinguish IDH1-R132H-positive from IDH1-R132H-negative tumours and to identify variables associated with early mortality.
Patients diagnosed with anaplastic astrocytic tumours were included. Magnetic resonance imaging was performed and immunohistochemistry was used to identify tumours with the IDH1-R132H mutation. Survival was assessed 12 months after diagnosis. Variables associated with IDH1-R132H status were identified by univariate and ROC analysis.
37 gliomas were studied; 18 were positive for the IDH1-R132H mutation. No tumours demonstrated a combined loss of chromosomes 1p/19q. Patients with IDH1-R132H-positive tumours were less likely to die within 12 months of diagnosis (17% vs. 47%; p=0.046), more likely to have tumours located in the frontal lobe (55% vs. 16%; p=0.015), and have a higher minimum apparent diffusion coefficient (1.115 x 10-3 mm2/sec vs. 0.838 x 10-3 mm2/sec; p=0.016), however, these variables demonstrated only moderate strength for predicting the IDH1-R132H mutation status (AUC=0.735 and 0.711, respectively). The Ki-67 index was significantly lower in IDH1-R132H-positive tumours (0.13 vs. 0.21; p=0.034). An increased risk of death was associated with contrast-enhancement ≥ 5 cm3 in patients with IDH1-R132H-positive tumours while edema ≥ 1 cm beyond the tumour margin and < 5 mitoses/mm2 were associated with an increased risk of death in patients with IDH1-R132H-negative tumours.
IDH1-R132H-positive and -negative anaplastic tumours demonstrate unique features. Factors associated with early mortality are also dependent on IDH1-R132H status and can be used to identify patients at high risk for death.
胶质母细胞瘤可原发发生,也可由低级别肿瘤转化而来;其中大多数存在异柠檬酸脱氢酶(IDH1)突变。间变性肿瘤是高级别胶质瘤,可能代表继发性胶质母细胞瘤演变的最后阶段,或早期原发性胶质母细胞瘤的初始表现。我们试图确定是否存在能够可靠区分IDH1-R132H阳性和IDH1-R132H阴性肿瘤的病理和/或放射学变量,并确定与早期死亡率相关的变量。
纳入诊断为间变性星形细胞瘤的患者。进行磁共振成像,并使用免疫组织化学鉴定具有IDH1-R132H突变的肿瘤。在诊断后12个月评估生存率。通过单因素分析和ROC分析确定与IDH1-R132H状态相关的变量。
共研究了37例胶质瘤;18例IDH1-R132H突变呈阳性。没有肿瘤显示1p/19q染色体联合缺失。IDH1-R132H阳性肿瘤患者在诊断后12个月内死亡的可能性较小(17%对47%;p=0.046),更有可能肿瘤位于额叶(55%对16%;p=0.015),且最小表观扩散系数更高(1.115×10-3mm2/秒对0.838×10-3mm2/秒;p=0.016),然而,这些变量在预测IDH1-R132H突变状态方面仅显示出中等强度(AUC分别为0.735和0.711)。IDH1-R132H阳性肿瘤的Ki-67指数显著更低(0.13对0.21;p=0.034)。IDH1-R132H阳性肿瘤患者中,对比增强≥5cm3与死亡风险增加相关,而IDH1-R132H阴性肿瘤患者中,肿瘤边缘外水肿≥1cm且有丝分裂<5个/平方毫米与死亡风险增加相关。
IDH1-R132H阳性和阴性间变性肿瘤具有独特特征。与早期死亡率相关的因素也取决于IDH1-R132H状态,可用于识别死亡风险高的患者。